Cel-Sci Corp (CVM)

$3.85 +0.32 (9.07%)
Market Cap 10.70M
Revenue (ttm) 0.00
Net Income (ttm) -26.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 563,600
Avg Vol 837,213
Day's Range N/A - N/A
Shares Out 3.03M
Stochastic %K 33%
Beta 0.30
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
phoenix31415
phoenix31415 Jul. 17 at 2:49 AM
$CVM Yesterday's daily short sale volume was 55.02% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market. The short borrow fee has increased to 106.48%!! and the number of currently shorted shares has increased to 269'000 shares. Furthermore, the short shares availability is down to 25'000 shares. With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!
0 · Reply
Yebego
Yebego Jul. 16 at 9:39 PM
$CVM WE CAN DO IT BOY LETS BREAK $4 AND WE WILL FLY !!!
0 · Reply
DeepThought
DeepThought Jul. 16 at 7:22 PM
$CVM Good Lord. What a clown are you! Blocked! Oooooooooof!🤡
1 · Reply
BozoJoeClownShow
BozoJoeClownShow Jul. 16 at 7:06 PM
$CVM Good lord, is this company still working on Multikine? I just saw they had an offering, so I read a few headlines. I used to be invested here in the late 90s and they were working on it then. Multiple large RS and it’s still a sub $4 stock nearly 30 years later. Oof
1 · Reply
CashNCarry
CashNCarry Jul. 16 at 4:54 PM
$CVM FRIDAY WILL BE A FUN DAY!!!!.......
2 · Reply
GTM86
GTM86 Jul. 16 at 4:48 PM
$CVM Break of 4 and this will fly
0 · Reply
TimingzEverything
TimingzEverything Jul. 16 at 4:42 PM
$CVM LOOKING GOOD!!!🏆 UPWARD CLIMB IN THE MAKING!! 📈🚀🚀🚀
0 · Reply
firf
firf Jul. 16 at 4:39 PM
$CVM
0 · Reply
Thebullrun
Thebullrun Jul. 16 at 4:17 PM
$CVM let’s rock!!
1 · Reply
DeepThought
DeepThought Jul. 16 at 3:51 PM
$CVM On the way to revaluation... 1) Signing of the contract. USD 10/share 2) Approval: USD 50/share 3) Year 2026: USD 250/share As GK would say: "I'll be back!"
1 · Reply
Latest News on CVM
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 14, 2025, 4:05 PM EDT - 2 days ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 5 days ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jul 11, 2025, 9:15 AM EDT - 5 days ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

Jun 18, 2025, 9:00 AM EDT - 4 weeks ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 7 weeks ago

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 2 months ago

CEL-SCI Announces Pricing of Public Offering

CEL-SCI Announces Proposed Public Offering

May 21, 2025, 4:05 PM EDT - 2 months ago

CEL-SCI Announces Proposed Public Offering

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025, 8:00 AM EDT - 2 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 2 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 2 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 23, 2025, 8:30 AM EDT - 3 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Apr 8, 2025, 9:51 AM EDT - 3 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 24, 2025, 9:00 AM EDT - 4 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 4 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 4 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 17, 2025, 8:00 AM EDT - 4 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Mar 14, 2025, 8:30 AM EDT - 4 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 5 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Feb 18, 2025, 8:30 AM EST - 5 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Jan 14, 2025, 9:00 AM EST - 6 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 7 months ago

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 7 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 7 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Dec 12, 2024, 9:15 AM EST - 7 months ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

Nov 8, 2024, 8:00 AM EST - 8 months ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Nov 7, 2024, 8:15 AM EST - 8 months ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 22, 2024, 9:15 AM EDT - 9 months ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Oct 1, 2024, 6:00 AM EDT - 10 months ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 16, 2024, 7:30 AM EDT - 10 months ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 10, 2024, 9:32 AM EDT - 11 months ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Sep 4, 2024, 9:00 AM EDT - 11 months ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 11 months ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 19, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

Feb 15, 2024, 8:00 AM EST - 1 year ago

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

Feb 13, 2024, 12:00 PM EST - 1 year ago

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

Feb 9, 2024, 8:30 AM EST - 1 year ago

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

Feb 6, 2024, 9:00 AM EST - 1 year ago

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

Jan 31, 2024, 9:00 AM EST - 1 year ago

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

Dec 22, 2023, 8:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

phoenix31415
phoenix31415 Jul. 17 at 2:49 AM
$CVM Yesterday's daily short sale volume was 55.02% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market. The short borrow fee has increased to 106.48%!! and the number of currently shorted shares has increased to 269'000 shares. Furthermore, the short shares availability is down to 25'000 shares. With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!
0 · Reply
Yebego
Yebego Jul. 16 at 9:39 PM
$CVM WE CAN DO IT BOY LETS BREAK $4 AND WE WILL FLY !!!
0 · Reply
DeepThought
DeepThought Jul. 16 at 7:22 PM
$CVM Good Lord. What a clown are you! Blocked! Oooooooooof!🤡
1 · Reply
BozoJoeClownShow
BozoJoeClownShow Jul. 16 at 7:06 PM
$CVM Good lord, is this company still working on Multikine? I just saw they had an offering, so I read a few headlines. I used to be invested here in the late 90s and they were working on it then. Multiple large RS and it’s still a sub $4 stock nearly 30 years later. Oof
1 · Reply
CashNCarry
CashNCarry Jul. 16 at 4:54 PM
$CVM FRIDAY WILL BE A FUN DAY!!!!.......
2 · Reply
GTM86
GTM86 Jul. 16 at 4:48 PM
$CVM Break of 4 and this will fly
0 · Reply
TimingzEverything
TimingzEverything Jul. 16 at 4:42 PM
$CVM LOOKING GOOD!!!🏆 UPWARD CLIMB IN THE MAKING!! 📈🚀🚀🚀
0 · Reply
firf
firf Jul. 16 at 4:39 PM
$CVM
0 · Reply
Thebullrun
Thebullrun Jul. 16 at 4:17 PM
$CVM let’s rock!!
1 · Reply
DeepThought
DeepThought Jul. 16 at 3:51 PM
$CVM On the way to revaluation... 1) Signing of the contract. USD 10/share 2) Approval: USD 50/share 3) Year 2026: USD 250/share As GK would say: "I'll be back!"
1 · Reply
drkazmd65
drkazmd65 Jul. 16 at 3:49 PM
$CVM - Bought some this morning. I figure that last offering has at least temporarily set a floor on the share prices. Now get a deal signed with that Saudi guys management!
0 · Reply
dcpanda
dcpanda Jul. 16 at 3:29 PM
$CVM Sign the damn agreement already.
0 · Reply
BioGLovesMe
BioGLovesMe Jul. 16 at 3:25 PM
$CVM Just in case you guys arent aware one person is getting paid by Geert to spam regurgitated garbage on multiple accounts. The known accounts are @SmallCapGrowth , @Johnm_ and @Thebullrun . Geert must be desperate if he's paying pennies to this moron to try and manipulate sentiment on a retail trading board.
1 · Reply
Johnm_
Johnm_ Jul. 16 at 12:39 PM
$CVM News - CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules https://finance.yahoo.com/news/cel-sci-announces-closing-5-200500941.html
1 · Reply
prophet777
prophet777 Jul. 16 at 11:50 AM
$CVM Back to 2 we go! Geert you are awesome! Where you have a “to sign agreement “ next? Greenland?
1 · Reply
DeepThought
DeepThought Jul. 16 at 11:27 AM
$CVM My assessment for Multikine MK from 2030-2035 By the way: Immunomedics (Single approved product!) was bought by Gilead for $21 billion.
1 · Reply
CashNCarry
CashNCarry Jul. 16 at 11:25 AM
$CVM
1 · Reply
phoenix31415
phoenix31415 Jul. 15 at 10:38 PM
$CVM Yesterday's daily short sale volume was 50.41% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market. The short borrow fee has increased to 57.91%!! and the number of currently shorted shares has increased to 269'000 shares. Furthermore, the short shares availability is down to 300 shares. With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!
1 · Reply
Johnyd
Johnyd Jul. 15 at 9:01 PM
$CVM gerd kersten is "imminent'
0 · Reply
Johnyd
Johnyd Jul. 15 at 7:00 PM
$CVM NO PARTNER!
0 · Reply
SmallCapGrowth
SmallCapGrowth Jul. 15 at 5:47 PM
$CVM News: CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules https://investorshangout.com/post/view?id=6776567
1 · Reply
WishIwasGolfing
WishIwasGolfing Jul. 15 at 2:37 PM
$CVM Maybe someone can explain this. Why are the posted number of CVM shares outstanding on multiple websites 5.32 million, but on the actual Cel-Sci website the number of CVM shares outstanding is listed as 3.03 million?
4 · Reply